OCULAR THERAPEUTIX, INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for the quarter ending 2025-06-30 was $94.03M.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for the quarter ending 2024-03-31 was $316.35M.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for the quarter ending 2023-09-30 was $708.00K.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for the quarter ending 2023-06-30 was $8.82M.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for fiscal 2024 was $316.35M, a 169.79% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for fiscal 2023 was $117.26M.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for fiscal 2020 was $224.50M, a 497.40% increase from fiscal 2019.
- OCULAR THERAPEUTIX, INC stock issued during period, value, new issues for fiscal 2019 was $37.58M, a 38.92% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-06-30 | $94.03M 10-Q · filed 2025-11-04 | |
| 2024-12-31 | $316.35M 10-K · filed 2025-03-03 | |
| 2024-03-31 | $316.35M 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $117.26M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $708.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $8.82M 10-Q · filed 2024-11-14 | |
| 2020-12-31 | $224.50M 10-K · filed 2023-03-06 | |
| 2020-06-30 | $50.02M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $12.69M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $37.58M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $18.62M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $5.07M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $4.95M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $61.53M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $12.85M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $8.39M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $34.70M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $29.24M 10-K · filed 2020-03-12 | |
| 2016-12-31 | $627.00K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $65.61M 10-K · filed 2018-03-08 | |
| 2014-12-31 | $69.52M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |